JP2018533947A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018533947A5 JP2018533947A5 JP2018521290A JP2018521290A JP2018533947A5 JP 2018533947 A5 JP2018533947 A5 JP 2018533947A5 JP 2018521290 A JP2018521290 A JP 2018521290A JP 2018521290 A JP2018521290 A JP 2018521290A JP 2018533947 A5 JP2018533947 A5 JP 2018533947A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- receptor agonist
- domain
- agonist protein
- cd27l
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 102000007499 CD27 Ligand Human genes 0.000 claims 18
- 108010046080 CD27 Ligand Proteins 0.000 claims 18
- 102100027207 CD27 antigen Human genes 0.000 claims 16
- 101000914511 Homo sapiens CD27 antigen Proteins 0.000 claims 16
- 235000018102 proteins Nutrition 0.000 claims 15
- 102000004169 proteins and genes Human genes 0.000 claims 15
- 108090000623 proteins and genes Proteins 0.000 claims 15
- 239000000018 receptor agonist Substances 0.000 claims 15
- 229940044601 receptor agonist Drugs 0.000 claims 15
- 150000001413 amino acids Chemical group 0.000 claims 12
- 108090000765 processed proteins & peptides Proteins 0.000 claims 8
- 235000001014 amino acid Nutrition 0.000 claims 7
- 229940024606 amino acid Drugs 0.000 claims 7
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 claims 5
- 210000004027 cell Anatomy 0.000 claims 4
- 102000039446 nucleic acids Human genes 0.000 claims 4
- 108020004707 nucleic acids Proteins 0.000 claims 4
- 150000007523 nucleic acids Chemical class 0.000 claims 4
- 229920001184 polypeptide Polymers 0.000 claims 4
- 102000004196 processed proteins & peptides Human genes 0.000 claims 4
- 102000018071 Immunoglobulin Fc Fragments Human genes 0.000 claims 3
- 108010091135 Immunoglobulin Fc Fragments Proteins 0.000 claims 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 3
- 239000004471 Glycine Substances 0.000 claims 2
- 101100273745 Homo sapiens CD70 gene Proteins 0.000 claims 2
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 claims 2
- 206010028980 Neoplasm Diseases 0.000 claims 2
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 claims 2
- 125000000613 asparagine group Chemical group N[C@@H](CC(N)=O)C(=O)* 0.000 claims 2
- 201000010099 disease Diseases 0.000 claims 2
- 208000015122 neurodegenerative disease Diseases 0.000 claims 2
- 239000013598 vector Substances 0.000 claims 2
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 claims 1
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 1
- ODHCTXKNWHHXJC-VKHMYHEASA-N 5-oxo-L-proline Chemical compound OC(=O)[C@@H]1CCC(=O)N1 ODHCTXKNWHHXJC-VKHMYHEASA-N 0.000 claims 1
- 108010011170 Ala-Trp-Arg-His-Pro-Gln-Phe-Gly-Gly Proteins 0.000 claims 1
- 208000023275 Autoimmune disease Diseases 0.000 claims 1
- 241000699802 Cricetulus griseus Species 0.000 claims 1
- 108091005804 Peptidases Proteins 0.000 claims 1
- 239000004365 Protease Substances 0.000 claims 1
- 108010076504 Protein Sorting Signals Proteins 0.000 claims 1
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 claims 1
- 208000034189 Sclerosis Diseases 0.000 claims 1
- -1 Ser or Gly Chemical class 0.000 claims 1
- 206010052779 Transplant rejections Diseases 0.000 claims 1
- 239000013543 active substance Substances 0.000 claims 1
- 239000002671 adjuvant Substances 0.000 claims 1
- 230000006907 apoptotic process Effects 0.000 claims 1
- 230000002917 arthritic effect Effects 0.000 claims 1
- 229940009098 aspartate Drugs 0.000 claims 1
- 235000003704 aspartic acid Nutrition 0.000 claims 1
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 claims 1
- 210000004899 c-terminal region Anatomy 0.000 claims 1
- 238000006243 chemical reaction Methods 0.000 claims 1
- 238000003776 cleavage reaction Methods 0.000 claims 1
- 239000003085 diluting agent Substances 0.000 claims 1
- 208000035475 disorder Diseases 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 230000004064 dysfunction Effects 0.000 claims 1
- 210000003527 eukaryotic cell Anatomy 0.000 claims 1
- 239000013604 expression vector Substances 0.000 claims 1
- 230000004927 fusion Effects 0.000 claims 1
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 claims 1
- 125000000404 glutamine group Chemical group N[C@@H](CCC(N)=O)C(=O)* 0.000 claims 1
- 125000003630 glycyl group Chemical group [H]N([H])C([H])([H])C(*)=O 0.000 claims 1
- 210000005260 human cell Anatomy 0.000 claims 1
- 208000015181 infectious disease Diseases 0.000 claims 1
- 208000027866 inflammatory disease Diseases 0.000 claims 1
- 208000019420 lymphoid neoplasm Diseases 0.000 claims 1
- 210000004962 mammalian cell Anatomy 0.000 claims 1
- 208000030159 metabolic disease Diseases 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- 230000004048 modification Effects 0.000 claims 1
- 238000012986 modification Methods 0.000 claims 1
- 230000035772 mutation Effects 0.000 claims 1
- 230000004770 neurodegeneration Effects 0.000 claims 1
- 230000007935 neutral effect Effects 0.000 claims 1
- 210000001672 ovary Anatomy 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 230000004481 post-translational protein modification Effects 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
- 210000001236 prokaryotic cell Anatomy 0.000 claims 1
- 230000002062 proliferating effect Effects 0.000 claims 1
- 238000000746 purification Methods 0.000 claims 1
- 229940043131 pyroglutamate Drugs 0.000 claims 1
- 102000005962 receptors Human genes 0.000 claims 1
- 108020003175 receptors Proteins 0.000 claims 1
- 102220082165 rs140083454 Human genes 0.000 claims 1
- 230000007017 scission Effects 0.000 claims 1
- 239000007787 solid Substances 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562245689P | 2015-10-23 | 2015-10-23 | |
| US62/245,689 | 2015-10-23 | ||
| PCT/EP2016/075579 WO2017068192A1 (en) | 2015-10-23 | 2016-10-24 | Single-chain cd27-receptor agonist proteins |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2018533947A JP2018533947A (ja) | 2018-11-22 |
| JP2018533947A5 true JP2018533947A5 (cg-RX-API-DMAC7.html) | 2019-12-05 |
| JP6917368B2 JP6917368B2 (ja) | 2021-08-11 |
Family
ID=57241060
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018521290A Active JP6917368B2 (ja) | 2015-10-23 | 2016-10-24 | 一本鎖ｃｄ２７受容体アゴニストタンパク質 |
Country Status (7)
| Country | Link |
|---|---|
| US (2) | US10844108B2 (cg-RX-API-DMAC7.html) |
| EP (1) | EP3364995B1 (cg-RX-API-DMAC7.html) |
| JP (1) | JP6917368B2 (cg-RX-API-DMAC7.html) |
| CN (1) | CN108430492B (cg-RX-API-DMAC7.html) |
| AU (1) | AU2016341409B2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3002602C (cg-RX-API-DMAC7.html) |
| WO (1) | WO2017068192A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3365448A1 (en) * | 2015-10-23 | 2018-08-29 | Apogenix AG | Single-chain cd137-receptor agonist proteins |
| WO2018127916A1 (en) | 2017-01-05 | 2018-07-12 | Kahr Medical Ltd. | A pd1-cd70 fusion protein and methods of use thereof |
| RU2769513C2 (ru) | 2017-01-05 | 2022-04-01 | Кахр Медикал Лтд. | Слитый белок pd1-4-1bbl и способы его применения |
| SI3565828T1 (sl) | 2017-01-05 | 2022-04-29 | Kahr Medical Ltd. | SIRP1 alfa-41BBL fuzijski protein in postopki za njegovo uporabo |
| WO2018127918A1 (en) | 2017-01-05 | 2018-07-12 | Kahr Medical Ltd. | A sirp alpha-cd70 fusion protein and methods of use thereof |
| US12286466B2 (en) | 2018-07-11 | 2025-04-29 | Kahr Medical Ltd. | PD1-4-1BBL variant fusion protein and methods of use thereof |
| WO2020012486A1 (en) | 2018-07-11 | 2020-01-16 | Kahr Medical Ltd. | SIRPalpha-4-1BBL VARIANT FUSION PROTEIN AND METHODS OF USE THEREOF |
| WO2021072127A2 (en) * | 2019-10-08 | 2021-04-15 | Fred Hutchinson Cancer Research Center | Engineered trimeric cd70 proteins and uses thereof |
| US20230212260A1 (en) | 2020-05-15 | 2023-07-06 | Apogenix Ag | Multi-specific immune modulators |
| WO2023088876A1 (en) | 2021-11-16 | 2023-05-25 | Apogenix Ag | Multi-specific immune modulators |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5573924A (en) * | 1992-09-08 | 1996-11-12 | Immunex Corporation | CD27 ligand |
| CZ302303B6 (cs) * | 1998-08-25 | 2011-02-16 | Merck Patent Gmbh | Homodimerní fúzní protein vykazující inhibicní aktivitu na angiogenezi, zpusob jeho produkce, molekula DNA a replikovatelný expresní vektor |
| AR025984A1 (es) | 1999-10-07 | 2002-12-26 | Maxygen Aps | Polipeptidos oligomericos de cadena simple |
| DE19963859A1 (de) | 1999-12-30 | 2001-07-12 | Apotech Res & Dev Ltd | Bi- oder Oligomer eines Di-, Tri-, Quattro- oder Pentamers von rekombinanten Fusionsproteinen |
| CA2314199A1 (en) | 2000-07-21 | 2002-01-21 | Robert Simoneau | C-chip |
| DE602004022390D1 (de) | 2003-03-26 | 2009-09-17 | Apogenix Gmbh | Verbesserte fc-fusionsproteine |
| DE102004014983A1 (de) | 2004-03-26 | 2005-10-20 | Univ Stuttgart | Rekombinante Polypeptide der Mitglieder der TNF Ligandenfamilie und deren Verwendung |
| JP2008537941A (ja) * | 2005-03-31 | 2008-10-02 | ゼンコー・インコーポレイテッド | 最適化特性を有するＦｃ変異体 |
| AU2007238704A1 (en) * | 2006-04-14 | 2007-10-25 | Amgen Inc. | Erythropoietin receptor agonists |
| EP2297209A4 (en) | 2008-06-03 | 2012-08-01 | Abbott Lab | IMMUNOGLOBULINS WITH TWO VARIABLE DOMAINS AND USES THEREOF |
| DK2604693T3 (en) | 2008-07-21 | 2016-05-30 | Apogenix Gmbh | Single-chain TNFSF molecules |
| US9169325B2 (en) * | 2010-04-13 | 2015-10-27 | Celldex Therapeutics, Inc. | Antibodies that bind human CD27 and uses thereof |
| CA2858806A1 (en) * | 2011-12-23 | 2013-06-27 | Innate Pharma | Enzymatic conjugation of polypeptides |
| PE20142242A1 (es) * | 2012-03-15 | 2015-01-08 | Janssen Biotech Inc | Anticuerpos humanos anti-cd27, metodos, y usos |
| JP2016531907A (ja) * | 2013-08-02 | 2016-10-13 | アデュロ・バイオテック・ホールディングス・ヨーロッパ・ベスローテン・フエンノートシャップＡｄｕｒｏ Ｂｉｏｔｅｃｈ Ｈｏｌｄｉｎｇｓ， Ｅｕｒｏｐｅ Ｂ．Ｖ． | 免疫刺激のためのｃｄ２７アゴニストと免疫チェックポイント阻害との組み合わせ |
| NO2776305T3 (cg-RX-API-DMAC7.html) | 2014-04-23 | 2018-01-27 |
-
2016
- 2016-10-24 CA CA3002602A patent/CA3002602C/en active Active
- 2016-10-24 JP JP2018521290A patent/JP6917368B2/ja active Active
- 2016-10-24 CN CN201680073684.5A patent/CN108430492B/zh active Active
- 2016-10-24 AU AU2016341409A patent/AU2016341409B2/en active Active
- 2016-10-24 EP EP16791344.1A patent/EP3364995B1/en active Active
- 2016-10-24 WO PCT/EP2016/075579 patent/WO2017068192A1/en not_active Ceased
-
2018
- 2018-04-19 US US15/956,964 patent/US10844108B2/en active Active
-
2020
- 2020-11-17 US US16/950,755 patent/US20210061880A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2018533947A5 (cg-RX-API-DMAC7.html) | ||
| RU2017141727A (ru) | Одноцепочечные белки-агонисты рецептора cd40 | |
| JP2019500850A5 (cg-RX-API-DMAC7.html) | ||
| US7820623B2 (en) | Conjugated toxin peptide therapeutic agents | |
| JP6272907B2 (ja) | 代謝障害の処置における組成物及び使用方法 | |
| CA2748314C (en) | Extended recombinant polypeptides and compositions comprising same | |
| JP7536294B2 (ja) | 抗体のＦｃ領域改変体 | |
| JP6040464B2 (ja) | 作用持続期間が増大し、免疫原性が減少した操作されたポリペプチド | |
| CN103403019B (zh) | 具有增强的作用持续时间的工程化多肽 | |
| JP2018533948A5 (cg-RX-API-DMAC7.html) | ||
| TW202225183A (zh) | Gdf15融合蛋白及其用途 | |
| KR20100017942A (ko) | 독소 펩티드 치료제 | |
| WO2014176373A2 (en) | Interleukin-10 compositions and uses thereof | |
| JP2010501191A5 (cg-RX-API-DMAC7.html) | ||
| US9731007B2 (en) | Tumour necrosis factor receptor fusion proteins and methods of using the same | |
| US20090252703A1 (en) | Use of alcohol co-solvents to improve pegylation reaction yields | |
| AU2016242905A1 (en) | Protoxin-II variants and methods of use | |
| JP2019501631A5 (cg-RX-API-DMAC7.html) | ||
| JP2018518485A (ja) | プロテアーゼ耐性脂質付加ｇｌｐ−１類似体 | |
| EP2597102A1 (en) | A novel fusion protein comprising an antibody light chain and a polypeptide binding to IL-17 | |
| US20240058422A1 (en) | Glucagon-like peptide-1 receptor antagonists | |
| ZA200709701B (en) | Toxin peptide therapeutic agents | |
| NZ741431B2 (en) | Long-acting fgf21 fusion proteins and pharmaceutical composition comprising same | |
| WO2014014816A2 (en) | Methods of treating glucose metabolism disorders | |
| WO2013151627A1 (en) | Methods of treating glucose metabolism disorders |